Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.
Lead Product(s): TFC-039
Therapeutic Area: Endocrinology Product Name: TFC-039
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Sirona Biochem Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 23, 2022
Details:
Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstendâ„¢ for Clinical Trial Approval.
Lead Product(s): Lidocaine,Prilocaine
Therapeutic Area: Psychiatry/Psychology Product Name: Senstend
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Regent Pacific
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 02, 2020